Gene expression and pathway analysis of ovarian cancer cells selected for resistance to cisplatin, paclitaxel, or doxorubicin

Gene expression and pathway analysis of ovarian cancer cells selected for resistance to cisplatin, paclitaxel, or doxorubicin

<p>Abstract</p> <p>Background</p> <p>Resistance to current chemotherapeutic agents is a major cause of therapy failure in ovarian cancer patients, but the exact mechanisms leading to the development of drug resistance remain unclear.</p> <p>Methods</p>...

Full description

Bibliographic Details
Main Authors:	Sherman-Baust Cheryl A, Becker Kevin G, Wood III William H, Zhang Yongqing, Morin Patrice J
Format:	Article
Language:	English
Published:	BMC 2011-12-01
Series:	Journal of Ovarian Research
Online Access:	http://www.ovarianresearch.com/content/4/1/21

Similar Items

MicroRNA expression and identification of putative miRNA targets in ovarian cancer.
by: Neetu Dahiya, et al.
Published: (2008-06-01)

Claudin-7 is frequently overexpressed in ovarian cancer and promotes invasion.
by: Neetu Dahiya, et al.
Published: (2011-01-01)

Cisplatin and doxorubicin induce distinct mechanisms of ovarian follicle loss; imatinib provides selective protection only against cisplatin.
by: Stephanie Morgan, et al.
Published: (2013-01-01)

First-line chemotherapy for advanced ovarian cancer: paclitaxel, cisplatin and the evidence
by: Sandercock, J, et al.
Published: (1998)

Claudin-containing exosomes in the peripheral circulation of women with ovarian cancer
by: Bristow Robert E, et al.
Published: (2009-07-01)

Resistance to paclitaxel in a cisplatin-resistant ovarian cancer cell line is mediated by P-glycoprotein.
by: Britta Stordal, et al.
Published: (2012-01-01)

Mifepristone prevents repopulation of ovarian cancer cells escaping cisplatin-paclitaxel therapy
by: Gamarra-Luques Carlos D, et al.
Published: (2012-06-01)

Transcriptome Remodeling in Gradual Development of Inverse Resistance between Paclitaxel and Cisplatin in Ovarian Cancer Cells
by: Jolanta Szenajch, et al.
Published: (2020-12-01)

Safety and Efficacy of Weekly Paclitaxel and Cisplatin Chemotherapy for Ovarian Cancer Patients with Hypersensitivity to Carboplatin
by: Shinichi Tate, et al.
Published: (2021-02-01)

NIPEC with Single-Dose Intraperitoneal Cisplatin and Paclitaxel in Stage III Epithelial Ovarian Cancer
by: Elroy Saldanha, et al.
Published: (2023-01-01)

No significant role for beta tubulin mutations and mismatch repair defects in ovarian cancer resistance to paclitaxel/cisplatin
by: Pinto Carla, et al.
Published: (2005-08-01)

Non-Steroidal Anti-Inflammatory Drugs Increase Cisplatin, Paclitaxel, and Doxorubicin Efficacy against Human Cervix Cancer Cells
by: Diana Xochiquetzal Robledo-Cadena, et al.
Published: (2020-12-01)

Cost-effectiveness of paclitaxel, doxorubicin, cyclophosphamide and trastuzumab versus docetaxel, cisplatin and trastuzumab in new adjuvant therapy of breast cancer in china
by: Qiaoping Xu, et al.
Published: (2021-02-01)

Phase 2 study of canfosfamide in combination with pegylated liposomal doxorubicin in platinum and paclitaxel refractory or resistant epithelial ovarian cancer
by: Moore Carla L, et al.
Published: (2010-03-01)

Neoadjuvant therapy of BRCA1-driven ovarian cancer by combination of cisplatin, mitomycin C and doxorubicin
by: Tatiana V. Gorodnova, et al.
Published: (2021-02-01)

Survival and Side Effects of Cisplatin/Cyclophosphamide and Carboplatin/Paclitaxel Adjuvant Chemotherapy in Stage IC-IV Ovarian Cancer
by: Unedo H Markus, et al.
Published: (2015-04-01)

Non-steroidal anti-inflammatory drugs decrease E2F1 expression and inhibit cell growth in ovarian cancer cells.
by: Blanca L Valle, et al.
Published: (2013-01-01)

The Profile of MicroRNA Expression and Potential Role in the Regulation of Drug-Resistant Genes in Cisplatin- and Paclitaxel-Resistant Ovarian Cancer Cell Lines
by: Dominika Kazmierczak, et al.
Published: (2022-01-01)

CHFR and Paclitaxel Sensitivity of Ovarian Cancer
by: Andrea E. Wahner Hendrickson, et al.
Published: (2021-11-01)

Inhibition of the IGF signaling pathway reverses cisplatin resistance in ovarian cancer cells
by: Juan Du, et al.
Published: (2017-12-01)

The Thrombospondin-1 Mimetic ABT-510 Increases the Uptake and Effectiveness of Cisplatin and Paclitaxel in a Mouse Model of Epithelial Ovarian Cancer
by: Nicole E. Campbell, et al.
Published: (2010-03-01)

PLGA nanoparticles co-delivering MDR1 and BCL2 siRNA for overcoming resistance of paclitaxel and cisplatin in recurrent or advanced ovarian cancer
by: Chitra Risnayanti, et al.
Published: (2018-05-01)

Remote loading paclitaxel–doxorubicin prodrug into liposomes for cancer combination therapy
by: Jiang Yu, et al.
Published: (2020-09-01)

Doxorubicin-induced ovarian toxicity
by: Rizel Shulamith, et al.
Published: (2010-03-01)

Onvansertib and paclitaxel combined in platinum-resistant ovarian carcinomas
by: Roberta Affatato, et al.
Published: (2022-05-01)

A novel small molecule LLL12B inhibits STAT3 signaling and sensitizes ovarian cancer cell to paclitaxel and cisplatin.
by: Ruijie Zhang, et al.
Published: (2021-01-01)

Systemic chemotherapy with doxorubicin, cisplatin and capecitabine for metastatic hepatocellular carcinoma
by: Bang Soo-Mee, et al.
Published: (2006-01-01)

Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent or refractory ovarian cancer: a systematic review and economic evaluation
by: Steven J Edwards, et al.
Published: (2015-01-01)

Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation
by: C Main, et al.
Published: (2006-03-01)

Tephrosin Suppresses the Chemoresistance of Paclitaxel-Resistant Ovarian Cancer via Inhibition of FGFR1 Signaling Pathway
by: Hee Su Kim, et al.
Published: (2023-11-01)

Role of microRNAs in regulation of doxorubicin and paclitaxel responses in lung tumor cells
by: Amirhosein Maharati, et al.
Published: (2023-07-01)

Impact of cetuximab plus cisplatin alone and cetuximab plus cisplatin and paclitaxel regimen on humanistic outcome in head and neck cancer
by: Avinash Khadela, et al.
Published: (2023-01-01)

Clinical trials and progress with paclitaxel in ovarian cancer
by: Sanjeev Kumar, et al.
Published: (2010-11-01)

FAM83B inhibits ovarian cancer cisplatin resistance through inhibiting Wnt pathway
by: Shanyang He, et al.
Published: (2021-01-01)

Esomeprazole Alleviates Cisplatin Resistance by Inhibiting the AKT/mTOR Pathway in Ovarian Cancer Cells
by: Duan J, et al.
Published: (2023-06-01)

Pegylated liposomal doxorubicin in ovarian cancer
by: Robert Strother, et al.
Published: (2009-08-01)

Salvage Chemotherapy with Cisplatin, Ifosfamide, and Paclitaxel in Aggressive Variant of Metastatic Castration-Resistant Prostate Cancer
by: Gunhild von Amsberg, et al.
Published: (2022-11-01)

Proteomic and metabolomic signatures of U87 glioblastoma cells treated with cisplatin and/or paclitaxel
by: Munazza Ahmed, et al.
Published: (2023-12-01)

Weekly chemotherapy with cisplatin and paclitaxel in advanced NSCLC: a phase II study
by: G. Buccheri, et al.
Published: (2016-02-01)

Adipose-Derived Stem Cells Primed with Paclitaxel Inhibit Ovarian Cancer Spheroid Growth and Overcome Paclitaxel Resistance
by: Cinzia Borghese, et al.
Published: (2020-04-01)